Moderna (MRNA) announced FDA approval of mFLUSIVA (mRNA-1010), its new seasonal influenza vaccine, for adults aged 50+. The regulatory clearance is a meaningful positive catalyst for the company’s vaccine pipeline and near-term outlook.
Moderna (MRNA) announced FDA approval of mFLUSIVA (mRNA-1010), its new seasonal influenza vaccine, for adults aged 50+. The regulatory clearance is a meaningful positive catalyst for the company’s vaccine pipeline and near-term outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
